These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 7160190)

  • 1. Monitoring rules for stopping accrual in comparative survival studies.
    Rubinstein LV; Gail MH
    Control Clin Trials; 1982 Dec; 3(4):325-43. PubMed ID: 7160190
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interim analyses, stopping rules and data monitoring in clinical trials in Europe.
    Buyse M
    Stat Med; 1993 Mar; 12(5-6):509-20. PubMed ID: 8493429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Center-Specific Modeling Predicts Cancer Trial Accrual More Accurately Than Investigators and Random Effects Modeling at 16 Cancer Centers.
    Tate WR; Abraham I; Cranmer LD
    JCO Clin Cancer Inform; 2019 Jun; 3():1-12. PubMed ID: 31173517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early termination of clinical trials with prolonged observation of individual patients: a case study.
    van Es GA; Tijssen JG; Lubsen J; van Strik R
    Stat Med; 1987 Dec; 6(8):927-37. PubMed ID: 3438618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantifying over-estimation in early stopped clinical trials and the "freezing effect" on subsequent research.
    Wang H; Rosner GL; Goodman SN
    Clin Trials; 2016 Dec; 13(6):621-631. PubMed ID: 27271682
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Joint monitoring and prediction of accrual and event times in clinical trials.
    Zhang X; Long Q
    Biom J; 2012 Nov; 54(6):735-49. PubMed ID: 22907686
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Building efficient comparative effectiveness trials through adaptive designs, utility functions, and accrual rate optimization: finding the sweet spot.
    Gajewski BJ; Berry SM; Quintana M; Pasnoor M; Dimachkie M; Herbelin L; Barohn R
    Stat Med; 2015 Mar; 34(7):1134-49. PubMed ID: 25640114
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interim futility analysis with intermediate endpoints.
    Goldman B; LeBlanc M; Crowley J
    Clin Trials; 2008; 5(1):14-22. PubMed ID: 18283075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Designs for group sequential tests.
    Fleming TR; Harrington DP; O'Brien PC
    Control Clin Trials; 1984 Dec; 5(4):348-61. PubMed ID: 6518769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Policies for study monitoring and interim reporting of results.
    Green SJ; Fleming TR; O'Fallon JR
    J Clin Oncol; 1987 Sep; 5(9):1477-84. PubMed ID: 3625262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Size of cancer clinical trials and stopping rules.
    Pocock SJ
    Br J Cancer; 1978 Dec; 38(6):757-66. PubMed ID: 369589
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Planning the duration of accrual and follow-up for clinical trials.
    Morgan TM
    J Chronic Dis; 1985; 38(12):1009-18. PubMed ID: 4066889
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modeling and validating Bayesian accrual models on clinical data and simulations using adaptive priors.
    Jiang Y; Simon S; Mayo MS; Gajewski BJ
    Stat Med; 2015 Feb; 34(4):613-29. PubMed ID: 25376910
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Accrual by groups in trials with discrete-time survival endpoints.
    Jóźwiak K; Moerbeek M
    Clin Trials; 2013 Feb; 10(1):32-42. PubMed ID: 23203992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Applicability of sample size calculations based on a comparison of proportions for use with the logrank test.
    Gail MH
    Control Clin Trials; 1985 Jun; 6(2):112-9. PubMed ID: 4006484
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early termination of cardiovascular trials as a consequence of poor accrual: analysis of ClinicalTrials.gov 2006-2015.
    Baldi I; Lanera C; Berchialla P; Gregori D
    BMJ Open; 2017 Jun; 7(6):e013482. PubMed ID: 28619765
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modeling and prediction of subject accrual and event times in clinical trials: a systematic review.
    Zhang X; Long Q
    Clin Trials; 2012 Dec; 9(6):681-8. PubMed ID: 22674642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. "Proving the null hypothesis" in clinical trials.
    Blackwelder WC
    Control Clin Trials; 1982 Dec; 3(4):345-53. PubMed ID: 7160191
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stopping rules and estimation problems in clinical trials.
    Hughes MD; Pocock SJ
    Stat Med; 1988 Dec; 7(12):1231-42. PubMed ID: 3231947
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Accounting for interim safety monitoring of an adverse event upon termination of a clinical trial.
    Dallas MJ
    J Biopharm Stat; 2008; 18(4):631-8; discussion 439-45. PubMed ID: 18607795
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.